Compare HII & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HII | RDY |
|---|---|---|
| Founded | 1886 | 1984 |
| Country | United States | India |
| Employees | 44000 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 9.9B |
| IPO Year | 2010 | 2001 |
| Metric | HII | RDY |
|---|---|---|
| Price | $272.26 | $12.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $411.33 | $16.90 |
| AVG Volume (30 Days) | 359.9K | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.52% | 0.52% |
| EPS Growth | ★ 10.24 | N/A |
| EPS | ★ 9.06 | N/A |
| Revenue | ★ $12,484,000,000.00 | N/A |
| Revenue This Year | $4.82 | $7.72 |
| Revenue Next Year | $6.28 | $3.50 |
| P/E Ratio | $30.59 | ★ $18.67 |
| Revenue Growth | ★ 8.23 | N/A |
| 52 Week Low | $263.62 | $11.36 |
| 52 Week High | $460.00 | $15.67 |
| Indicator | HII | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 53.86 |
| Support Level | $263.62 | $12.09 |
| Resistance Level | $296.19 | $12.48 |
| Average True Range (ATR) | 6.79 | 0.18 |
| MACD | -1.30 | 0.03 |
| Stochastic Oscillator | 6.70 | 82.25 |
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships, including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.